Table 1.
Patient characteristics
| Hospital | |||||
|---|---|---|---|---|---|
| Factor | All | Niigata (training set) | Nagaoka (validation set) | ||
| Number of patients | N = 217 | N = 148 | N = 69 | P‐value | |
| Age (range) | 38 y (10‐67) | 38 y (10‐66) | 39 y (14‐67) | 0.196 | |
| Age (%) | <40 y | 119 (54.8) | 83 (56.1) | 36 (52.2) | |
| ≤40 y | 98 (45.2) | 65 (43.9) | 33 (47.8) | 0.661 | |
| Sex (%) | Male | 111 (51.2) | 74 (50.0) | 37 (53.6) | 0.663 |
| Female | 106 (48.8) | 74 (50.0) | 32 (46.4) | ||
| Diagnosis (%) | AML | 135 (62.2) | 97 (65.5) | 38 (55.1) | 0.176 |
| ALL | 82 (37.8) | 51 (34.5) | 31 (44.9) | ||
| with (9;22) | 31 (37.8) | 18 (35.3) | 13 (41.9) | 0.64 | |
| Hospital (%) | Niigata | 148 (68.2) | |||
| Nagaoka | 69 (31.8) | ||||
| rDRI (%) | LOW | 14 (6.5) | 10 (6.8) | 4 (5.8) | 0.574 |
| INT | 121 (55.8) | 78 (52.7) | 43 (62.3) | ||
| HI | 51 (23.5) | 36 (24.3) | 15 (21.7) | ||
| VH | 31 (14.3) | 24 (16.2) | 7 (10.1) | ||
| Graft source (%) | BM | 123 (56.7) | 85 (57.4) | 38 (55.1) | 0.115 |
| PBSC | 25 (11.5) | 19 (12.8) | 6 (8.7) | ||
| HAPLO‐PBSC | 22 (10.1) | 18 (12.2) | 4 (5.8) | ||
| CB | 47 (21.7) | 26 (17.6) | 21 (30.4) | ||
| Donor type (%) | Unrelated | 120 (55.3) | 77 (52.0) | 43 (62.3) | 0.187 |
| Related | 97 (44.7) | 71 (48.0) | 26 (37.7) | ||
| Conditioning (%) including | MAC | 169 (77.9) | 110 (74.3) | 59 (85.5) | 0.079 |
| RIC | 48 (22.1) | 38 (25.7) | 10 (14.5) | ||
| Thymoglobulin | 14 (6.5) | 13 (8.8) | 1 (1.4) | ||
| Post cyclophosphamide | 8 (3.7) | 5 (3.4) | 3 (4.3) | ||
| HCT_CI score (%) | ≤2 | 183 (84.3) | 126 (85.1) | 57 (82.6) | 0.69 |
| ≤3 | 34 (15.7) | 22 (14.9) | 12 (17.4) | ||
| NRM (%) | Yes | 42 (19.4) | 29 (19.6) | 13 (18.8) | 1 |
| Using TBI (%) | No | 19 (8.8) | 17 (11.5) | 2 (2.9) | 0.041 |
| Yes | 197 (91.2) | 131 (88.5) | 66 (97.1) | ||
| Relapse within 1 y (%) | Yes | 69 (31.8) | 51 (34.5) | 18 (26.1) | 0.273 |
| OS | Months (range) | 28.9 (1.2‐223.2) | 31.4 (1.2‐223.2) | 27.3 (1.2‐127.1) | 0.382 |
| RFS | Months (range) | 20.6 (1.0‐223.2) | 20.4 (1.0‐223.2) | 20.7 (1.0‐124.8) | 0.816 |
No significant differences were observed between the training and validation sets.
Abbreviations: ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; BM, bone marrow; CB, cord blood; HAPLO‐PBSC, PBSC from haploidentical donors; HCT‐CI, Hematopoietic Cell Transplantation‐Comorbidity Index; HI, high risk; INT, intermediate risk; LOW, low risk; MAC, myeloablative conditioning; NRM, nonrelapse mortality; OS, overall survival; PBSC, peripheral blood stem cells; rDRI, the Refined Disease Risk Index; RFS, relapse‐free survival; RIC, reduced intensity conditioning; TBI, total body irradiation; VH, very high risk.